• Molecular NameMedroxyprogesterone
  • SynonymCBP-1011; Hydroxymethylprogesterone; MAP; Medroprogesterone Acetate; Medrossiprogesterone [Dcit]; Medroxiprogesterona [INN-Spanish]; Medroxiprogesteronum; Medroxyprogesteron; Medroxyprogesteron acetate; Medroxyprogesteronum [INN-Latin]
  • Weight344.495
  • Drugbank_IDDB00603
  • ACS_NO520-85-4
  • Show 3D model
  • LogP (experiment)3.606
  • LogP (predicted, AB/LogP v2.0)3.43
  • pkaN/A
  • LogD (pH=7, predicted)3.43
  • Solubility (experiment)0.0222 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.33
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds1
  • TPSA54.37
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA progestin, and is commonly a component of hormonal contraceptives. It can be used in the treatment of endometriosis, abnormal menstrual bleeding or amenorrhea.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed from GI tract
  • Caco_2N/A
  • Bioavailability15.0
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life50 days
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A